Chronic lymphocytic leukemia (CLL) is diagnosed primarily through a simple blood test, not a bone marrow biopsy. The key threshold: you need at least 5,000 abnormal B lymphocytes per microliter of blood, sustained for at least three months. Most people discover they have CLL after routine bloodwork reveals an unexpectedly high white blood cell count, often before any symptoms appear.
The Blood Test That Confirms CLL
A complete blood count (CBC) is almost always the first clue. It shows an elevated lymphocyte count, which prompts further testing. But a high lymphocyte count alone isn’t enough for a diagnosis. Many conditions, from infections to other blood cancers, can raise lymphocyte levels.
The confirmatory step is a test called flow cytometry, which identifies the exact type of cells circulating in your blood. In CLL, the abnormal cells display a very specific combination of surface proteins. They carry markers called CD5 and CD19 together, which is unusual because CD5 normally appears on a different type of immune cell. CLL cells also show unusually dim levels of CD20 and are strongly positive for CD23 and CD200. This protein fingerprint is distinctive enough that flow cytometry on a blood sample can confirm CLL without any tissue biopsy in most cases.
Another clue that often shows up early is the appearance of “smudge cells” on a standard blood smear. These are CLL cells that rupture during slide preparation because they’re more fragile than normal lymphocytes. Virtually all CLL patients have at least some smudge cells, and they’re rare in other blood disorders, making them a useful early signal. Interestingly, a higher percentage of smudge cells is actually associated with better outcomes: patients with more than 30% smudge cells on their blood smear had a 10-year survival rate of 80%, compared to 50% for those with 30% or fewer.
CLL vs. SLL vs. MBL
Three closely related conditions exist on a spectrum, and the diagnosis depends on where you fall. If your blood has fewer than 5,000 abnormal B lymphocytes per microliter and you have no enlarged lymph nodes or organs, the diagnosis is monoclonal B-cell lymphocytosis (MBL), a precursor condition that may never progress. If your count is below 5,000 but you do have enlarged lymph nodes, spleen involvement, or other tissue involvement, the diagnosis is small lymphocytic lymphoma (SLL), which is essentially the same disease as CLL but presenting in the lymph nodes rather than the blood. At 5,000 or above, it’s CLL. The cells look identical under a microscope and carry the same surface proteins in all three conditions.
Genetic Tests That Shape Your Outlook
Once CLL is confirmed, genetic testing on the leukemia cells provides critical information about how the disease is likely to behave. These tests don’t change the diagnosis itself, but they heavily influence when and how treatment might eventually be needed.
A test called FISH (fluorescence in situ hybridization) checks for chromosomal abnormalities in the CLL cells. The most common finding is a deletion on chromosome 13, present in roughly 40% of newly diagnosed patients and associated with a favorable prognosis. Deletion on chromosome 11 (found in about 9% of cases) is linked to faster disease progression and bulkier lymph node involvement. The highest-risk finding is a deletion on chromosome 17, seen in about 10-14% of patients, which places you in the most aggressive risk category with the shortest expected survival times.
The chromosome 17 deletion is particularly important because it knocks out TP53, a gene that helps cells respond to chemotherapy. About 30-40% of patients with TP53 problems carry only a mutation in the gene without a visible chromosome deletion, meaning the FISH test alone would miss them. For this reason, guidelines recommend testing for TP53 mutations separately using gene sequencing, not just FISH. Both tests should be performed before starting any treatment, because patients with TP53 abnormalities respond poorly to traditional chemotherapy and need targeted therapies instead.
IGHV Mutation Status
One of the most informative tests checks whether a specific gene in the CLL cells (called IGHV) has undergone mutations. “Mutated” IGHV is the better result. In a large Danish population study, patients with unmutated IGHV had significantly shorter survival from diagnosis and responded less durably to treatment. After intensive chemotherapy-based treatment, 91% of patients with mutated IGHV were still in remission at three years, compared to just 68% of those with unmutated IGHV. With less intensive treatment, the gap widened further: 91% versus 53% at three years. This single test is one of the strongest predictors of how CLL will behave over time.
When Bone Marrow Biopsy Is Needed
Unlike many blood cancers, CLL does not require a bone marrow biopsy for diagnosis. The combination of blood counts and flow cytometry is sufficient. Bone marrow biopsy may be performed later if your doctor needs to evaluate unexplained drops in red blood cells or platelets, assess your response to treatment, or rule out other conditions that might be developing alongside CLL. But it’s not part of the standard initial diagnostic workup.
How CLL Is Staged
After diagnosis, your doctor determines the stage of disease using physical examination and blood counts. In the United States, the Rai staging system is most common. In Europe, the Binet system is preferred. Both rely on straightforward clinical findings rather than imaging scans.
The Rai system has five stages:
- Stage 0: High lymphocyte count only, with no enlarged lymph nodes, liver, or spleen, and normal hemoglobin and platelets. This is low-risk, and many people remain at this stage for years.
- Stage I: High lymphocyte count plus enlarged lymph nodes.
- Stage II: High lymphocyte count plus an enlarged liver or spleen, with or without enlarged lymph nodes.
- Stage III: Hemoglobin drops below 11 g/dL (anemia), regardless of other findings.
- Stage IV: Platelet count drops below 100,000 per microliter, regardless of other findings.
The Binet system simplifies this into three groups. Stage A means fewer than three areas of enlarged lymph nodes with normal hemoglobin and platelets. Stage B means three or more areas of enlarged lymph nodes, still with adequate blood counts. Stage C means hemoglobin below 10 g/dL or platelets below 100,000, regardless of lymph node involvement.
Staging tells you and your doctor how advanced the disease is right now, while the genetic tests described above predict how it’s likely to behave going forward. Together, they determine whether you need treatment immediately or can be safely monitored with regular blood tests, an approach called “watch and wait” that is standard for early-stage, low-risk CLL.